DGAP-Adhoc: Evotec and Bristol Myers Squibb extend and expand strategic partnership
DGAP-Ad-hoc: Evotec SE / Key word(s): Miscellaneous
Evotec and Bristol Myers Squibb extend and expand strategic partnership
10-May-2022 / 16:29 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Hamburg, Germany – Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) announces today that the Company has extended and expanded its partnership with Bristol Myers Squibb (NYSE:BMY) in targeted protein degradation, originally signed in 2018.
Aim of the eight-year extension is to develop a broad pipeline of molecular glue degraders which are small, drug-like compounds. Bristol Myers Squibb is a leader in this field in particular based on its unique library CELMoD®.
Under the terms of the agreement, Evotec’s proprietary EVOpanOmics and EVOpanHunter platforms as well as AI/ML-based drug discovery and development platforms will be leveraged.
Evotec receives an upfront payment of $ 200 m and expects to obtain further performance-based, near-term and programme-based milestone payments, resulting in a deal potential of $ 5 bn with additional tiered royalties on product sales.
– End of ad hoc release –
Contact: Dr Werner Lanthaler, Chief Executive Officer, Evotec SE, Manfred Eigen Campus, Essener Bogen 7, 22419 Hamburg, Germany, Phone: +49.(0)40.560 81-242, [email protected]
10-May-2022 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
|
Language: |
English |
Company: |
Evotec SE |
|
Manfred Eigen Campus / Essener Bogen 7 |
|
22419 Hamburg |
|
Germany |
Phone: |
+49 (0)40 560 81-0 |
Fax: |
+49 (0)40 560 81-222 |
E-mail: |
[email protected] |
Internet: |
www.evotec.com |
ISIN: |
DE0005664809 |
WKN: |
566480 |
Indices: |
MDAX, TecDAX |
Listed: |
Regulated Market in Berlin, Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; Nasdaq |
EQS News ID: |
1348655 |
|
End of Announcement |
DGAP News Service |
1348655 10-May-2022 CET/CEST
Die wichtigsten Finanzdaten auf einen Blick
|
|
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023e |
Umsatzerlöse1 |
257,63 |
375,41 |
446,44 |
500,92 |
618,03 |
751,45 |
835,00 |
EBITDA1,2 |
57,22 |
95,46 |
123,14 |
51,77 |
101,65 |
102,51 |
122,00 |
EBITDA-Marge3 |
22,21 |
25,43 |
27,58 |
10,33 |
16,45 |
13,64 |
|
EBIT1,4 |
37,50 |
77,46 |
62,59 |
48,52 |
41,00 |
20,85 |
0,00 |
EBIT-Marge5 |
14,56 |
20,63 |
14,02 |
9,69 |
6,63 |
2,78 |
0,00 |
Jahresüberschuss1 |
24,00 |
84,06 |
37,23 |
6,25 |
215,51 |
-175,66 |
0,00 |
Netto-Marge6 |
9,32 |
22,39 |
8,34 |
1,25 |
34,87 |
-23,38 |
0,00 |
Cashflow1,7 |
10,83 |
156,24 |
42,22 |
44,72 |
122,24 |
203,11 |
0,00 |
Ergebnis je Aktie8 |
0,16 |
0,46 |
0,25 |
0,04 |
1,30 |
-0,99 |
-0,50 |
Dividende8 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
Quelle: boersengefluester.de und Firmenangaben
Geschäftsbericht 2022 - Kostenfrei herunterladen.
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de
Wirtschaftsprüfer: BDO
|
INVESTOR-INFORMATIONEN |
©boersengefluester.de |
Evotec |
WKN |
Kurs in € |
Einschätzung |
Börsenwert in Mio. € |
566480 |
13,700 |
Halten |
2.432,33 |
KGV 2025e |
KGV 10Y-Ø |
BGFL-Ratio |
Shiller-KGV |
20,15 |
35,16 |
0,56 |
77,40 |
KBV |
KCV |
KUV |
EV/EBITDA |
2,13 |
11,98 |
3,24 |
24,60 |
Dividende '22 in € |
Dividende '23e in € |
Div.-Rendite '23e in % |
Hauptversammlung |
0,00 |
0,00 |
0,00 |
10.06.2024 |
Q1-Zahlen |
Q2-Zahlen |
Q3-Zahlen |
Bilanz-PK |
22.05.2024 |
14.08.2024 |
08.11.2023 |
24.04.2024 |
Abstand 60Tage-Linie |
Abstand 200Tage-Linie |
Performance YtD |
Performance 52 Wochen |
0,12% |
-22,78% |
-35,62% |
-22,82% |
|
|